The mCRC Journey Treatment Sequencing and Real-World Decisions

The mCRC Journey: Treatment Sequencing and Real-World Decisions (Epi. 2)

Join medical oncologists Dr. Tiago Bianchi and Dr. Raji Shameem for Episode 2 of our "Voices in Colorectal Cancer" Series as they navigate the complex, guideline-based, and real-world treatment landscape for metastatic colorectal cancer (mCRC).

This episode delves into current practice, informed by key insights from a recent FLASCO survey:

• Molecular Profiling: The doctors confirm molecular profiling is widely adopted (86% of respondents test patients >90% of the time). However, they discuss persistent gaps related to insurance barriers and challenges with specimen quality.
• Sequencing Strategies: Explore the current NCCN mCRC treatment pathways and the variety in real-world sequencing decisions after initial chemotherapy. The discussion contrasts community versus academic approaches to later-line decision-making.
• New Horizons: Learn where biomarker-agnostic therapies fit into the mCRC journey and how novel treatments are integrated into existing protocols.
• Access & Trials: The doctors address common access issues, prior authorization, and payer challenges that complicate care. Finally, they discuss the critical—yet often delayed—process of clinical trial referral, highlighting timing and lack of awareness as the primary barriers.

Tune in to understand the complexities of mCRC management, from biomarker testing to strategic sequencing and overcoming systemic access hurdles.